The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
New Gene Therapy Product ARU-1801 Shows Durable, Safe Sickle Cell Effect
The second process of ARU-1801 in a new patient resulted in up to 4 times greater engraftment of transduced hematopoietic stem cells and progenitors at 6 months.
Daratumumab Plus Pomalidomide Significantly Benefits Relapsed/Refractory Multiple Myeloma
An interview with a Janssen expert on the growing portfolio and newest data for daratumumab.
Cerebral Arteriopathy Risk More Common in Sickle Cell Anemic Children
The sickle cell disease subtype is associated with increased risk among patients as young as 2 years old.
New PKR Activator for Sickle Cell Shows Promising Safety, Efficacy Results
In data presented at ASH 2020, FT-4204 shows early potential in being safe, efficacious treatment for sickle cell disease.
Mitapivat Demonstrates Safety, Tolerability Among Sickle Cell Disease Patients
The ongoing phase I study also demonstrates that the drug is associated with an increase in Hb from baseline with a concomitant decrease in hemolytic markers.
Early Initiation of Rivipansel for VOC in Sickle Cell Disease
Early initiation reduces hospital stays and length of IV opioid use.
Exercise-Induced Vital Sign Changes May Predict Sickle Cell Prognosis
Analyses of vital sign changes from the 6-minute walk test may be indicative of cardiopulmonary function and potential survival among patients with sickle cell disease.
Anticoagulant, Antiplatelet Use Not Linked to Better COVID-19 Outcomes
The new findings show worsened outcomes among particular comorbid patient groups, as well as minority patients.
Jeffrey Wolf, MD: Optimizing Multiple Myeloma Assessment
A discussion on what the future of monitoring the rare disease may entail, and how COVID-19 interrupted in-person assessment earlier this year.
Venetoclax-Obinutuzumab Significantly Improves Chronic Lymphocytic Leukemia Survival
The combination therapy was linked to a record phase 3 progression-free survival rate among a subpopulation of patients with the rare cancer.
Measurable Residual Disease Could Improve Multiple Myeloma Treatment Decisions
A discussion with a study author and longtime expert on improving monitoring of the rare disease.
Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients
The furthest-progressed gene-edited therapy for a genetic disease reported historic efficacy data in ongoing phase 1/2 trials.
mHealth App Improves Sickle Cell Disease Symptoms
The app improved pain, fatigue, and quality of life in children with the disease.
Cognitive, Emotional Measures Linked to Sickle Cell Healthcare Utilization
A study finds that children with cognitive or emotional deficits trended towards an increased healthcare utilization.
LentiGlobin for Sickle Cell Has Potential to Improve Health-Related Quality of Life
Patients with baseline PROMIS-57 scores worse than population norms reported clinically significant improvements in 6 of 8 domains at 12 months post-treatment.
High COVID-19 False-Negative Rate Among Patients With Hematological Malignancies
Faster initiation of COVID-19 treatment is associated with better outcomes in patients with hematological malignancies.
COVID-19 and Hematological Diseases Linked to High Mortality Rate
Patients with acute myeloid leukemia or myelodysplastic syndromes are at especially increased risk for increased disease severity and death.
Study Reports on Thrombotic Rates Among COVID-19 Patients
Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.
Targeted Gene Editing May Provide a Sickle Cell Disease Cure
Early assessment from an Australian team of investigators is targeting a pathway linked to hemoglobin expression.
Novel Genetic Loci May Be Linked with HbF Expression in Sickle Cell Children
High levels of fetal hemoglobin have previously been linked to the mitigation of morbidity and mortality of sickle cell anemia.
CPX-351 Plus Venetoclax Tolerable in Patients with Acute Myeloid Leukemia
Those without prior exposure to venetoclax experienced the most benefit.
Gaurav Ghosh, MD: New Patch Test for EoE
In a poster presented at ACG, investigators find a new patch test could help patients who are not responding to PPI therapy.
Thoughts on AAO 2020: Uveitis Subspecialty Day
A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.
Raymond Douglas, MD, PhD: The Shift to Telemedicine in Ophthalmology
Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.
Development of Geographic Atrophy is Similar Across Ranibizumab Dosing Regimens
A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.
New Study Examines Role of Anti-VEGF Injections on Treatment Patterns
There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.
PRN Injections Yields Improvements for Diabetic Retinopathy Patients
In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.
Ranibizumab Associated with Improved Choroid Flow in DME
A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.
Nadia Waheed, MD, MPH: OCT Angiography Predicts DR Progression
A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.
Ehsan Rahimy, MD: The Importance of Continued Geographic Atrophy Screening
A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.